Updated:
Focalpoint Ventures
Focalpoint Ventures conducts its investment activities under the XEIA Venture Partners brand, investing in early-stage companies building what it terms...
Focalpoint Ventures
Focalpoint Ventures conducts its investment activities under the XEIA Venture Partners brand, investing in early-stage companies building what it terms 'Human 3' — a thesis centered on the convergence of life sciences, artificial intelligence, hardware, software, and deep tech. The firm's stated philosophy is that the 'user experience' of the human body and mind is overdue for an upgrade, and it targets startups operating at this intersection. XEIA's strategy is concentrated on seed and early-stage venture investments in companies that combine health tech, neurotechnology, and computational biology. The firm's portfolio approach explicitly defies conventional sector categorization, blending hardware, software, and biotech into single entities. Publicly named focus areas include psychoactive pharmacology, neurotechnology applications such as brain-computer interfaces, and longevity science. Operational details regarding the firm's scale, team size, or total capital deployed are not publicly disclosed. The firm maintains its headquarters in Los Angeles and signals an advisory network that includes specialists in medicinal chemistry, psychoactive pharmacology, AI, and neurodegeneration, including the director of MIT's Aging Brain Initiative. Focalpoint Ventures differentiates itself structurally through its narrow philosophical mandate — 'Human 3' — rather than a broad multi-sector venture approach. The firm's thesis commits it to a specific, science-heavy edge of the venture landscape where deal flow depends on deep domain expertise in both biological systems and computational methods, a posture that shapes its likely sourcing and diligence distinct from generalist early-stage investors.
General information
Firm type
Venture Capital
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Los Angeles
Corporate office
Los Angeles, CA, United States
Sector focus
Frequently asked questions
What is Focalpoint Ventures' investment thesis?
The firm invests under the XEIA Venture Partners brand with a thesis it calls 'Human 3,' targeting the convergence of life sciences, AI, hardware, and deep tech to advance human health, wellbeing, and performance. Its portfolio companies combine these disciplines in ways that often defy traditional categorization.
What investment stages does Focalpoint Ventures target?
XEIA Venture Partners focuses on early-stage startups. The firm has not publicly specified a preferred check size or series range, but its positioning points to seed and early-venture rounds for companies still forming their core scientific and product foundations.
Which sectors does Focalpoint Ventures explicitly avoid?
The firm is explicitly concentrated on health, wellbeing, and performance — it does not invest in general SaaS, enterprise software, fintech, or consumer internet plays that fall outside the intersection of human biology and technology. Its narrow 'Human 3' mandate implicitly excludes sectors where the upgrade of the human body or mind is not the central value proposition.
Who runs investment decisions at Focalpoint Ventures?
The firm has not publicly named its investment committee or disclosed the identities of its general partners on its website or in available public filings. It signals an advisory network that includes a medicinal chemist, a psychoactive pharmacologist, and the director of MIT's Aging Brain Initiative, suggesting these domain experts inform technical evaluation.
How does Focalpoint Ventures source proprietary deal flow?
Based on its thesis, deal flow likely depends on deep networks within academic and commercial life sciences, neurotechnology, and computational biology communities. The firm's association with advisors at institutions like MIT indicates a sourcing model rooted in scientific research hubs and frontier bio-hardware labs, though the firm has not described its sourcing process publicly.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: